Intellectual Property India Publishes Patent Application for 'Modified Hematopoietic Stem Cells And Progenies Thereof' Filed by Garuda Therapeutics, Inc.

MUMBAI, India, Aug. 8 -- Intellectual Property India has published a patent application (202517042448 A) filed by Garuda Therapeutics, Inc., Cambridge, U.S.A., on May 1, for 'modified hematopoietic stem cells and progenies thereof.'

Inventor(s) include Shah, Dhvanit.

The application for the patent was published on Aug. 8, under issue no. 32/2025.

According to the abstract released by the Intellectual Property India: "The present disclosure in various aspects and embodiments relates to cell compositions (and methods for making or using the same) comprising hematopoietic stem cells (HSCs) and/or hematopoietic stem progenitor cells (HSPCs), where the HSCs and/or HSPCs have one or more endogenous genes modified in their expression, to thereby avoid or reduce targeting of these cells by targeted therapies. In an aspect, the disclosure provides such HSCs and/or HSPCs from gene-edited human induced pluripotent stem ceils (iPSCs)."

The patent application was internationally filed on Oct. 05, 2023, under International application No.PCT/US2023/076091.

Disclaimer: Curated by HT Syndication.